Dr. David Anderson, VBI's Chief Scientific Officer, discusses VBI's eVLP Platform and the company's unique approach to vaccine development.
VBI’s eVLP Platform allows for the design of enveloped (“e”) virus-like particle (“VLP”) vaccines. eVLPs are an innovative new class of synthetic vaccines that are designed to closely mimic the structure of viruses. VBI’s eVLP Platform provides a stable foundation that is suitable for a wide array of prophylactic and therapeutic vaccine candidates.Learn More
Many vaccines and biologics are highly sensitive to temperature and physical stress which may lead to a loss in potency or reduced safety, limiting protective benefits or therapeutic effects. VBI’s Lipid Particle Vaccines (“LPV”) Platform is a proprietary formulation and process designed to preserve the stability and potency of vaccines and biologics.Learn More